Regulatory failure for DrugSorb-ATR
The product candidate needs FDA and Health Canada authorization before meaningful North American sales can begin.
- Scope
- U.S. and Canada growth
- Materiality
- high
Cytosorbents Corp
Cytosorbents Corp develops blood purification and adsorption devices used in critical care, cardiac surgery, and other acute care settings. Its lead product, CytoSorb, is sold in many countries outside the U.S., while the company is also pursuing regulatory approvals for DrugSorb-ATR and other product candidates in North America.
−36,5 %
71,5 %
−22,1 %
+4,1 %
2.13
1.58
| % | |
|---|---|
| CytoSorb therapy | 70% Hemoadsorption cartridges used in critical care and cardiothoracic surgery to remove inflammatory mediators and selected substances from blood. |
| DrugSorb-ATR | 10% A product candidate designed to remove antithrombotic drugs around surgery to reduce bleeding risk. |
| Other human devices | 10% Includes ECOS-300CY, PuriFi and related device offerings used with extracorporeal blood treatment systems. |
| Veterinary products | 5% VetResQ products used in animal critical care and veterinary applications. |
| Services and support | 5% Regulatory, clinical, and commercialization support tied to product adoption and market expansion. |
The company sells primarily to hospitals, intensive care units, and cardiac surgery teams that use its devices in...
- Critical care hospitalsprimary
Buy CytoSorb for ICU patients with sepsis, septic shock, respiratory failure, and other acute inflammatory conditions.
- Cardiothoracic surgery centersprimary
Use CytoSorb or DrugSorb-ATR-related therapies to manage bleeding and drug-removal needs around surgery.
- Physicians and clinical adoptersprimary
Influence purchasing by adopting the therapy, generating clinical evidence, and driving protocol inclusion.
- Payers and reimbursement decision-makerssecondary
Assess whether the therapy is reimbursed and economically justified, affecting adoption speed.
- Veterinary customersemerging
Buy VetResQ for animal critical care use, a smaller but strategically relevant niche.
CytoSorbents is headquartered in Princeton, New Jersey, but its commercial footprint is international, with CytoSorb...
- •Headquartered in Princeton, New Jersey, United States
- •CytoSorb sold in more than 70 countries worldwide
- •European Union is the core approved market for CytoSorb
- •U.S. commercialization depends on FDA authorization for key products
- •Canada commercialization is tied to Health Canada review of DrugSorb-ATR
Management is focused on expanding commercial adoption while advancing regulatory approvals for DrugSorb-ATR in the U.S...
01
U.S. regulatory approval for DrugSorb-ATRshort-term
Approval would unlock a large new market and materially improve commercialization prospects.
02
Cost reduction and operating disciplineshort-term
Lower spending is needed to preserve liquidity and reach cash-flow breakeven.
03
Clinical and market adoption expansionmedium-term
Broader physician acceptance and guideline inclusion are needed for sustained sales growth.
04
International commercialization of CytoSorbmedium-term
The company already has regulatory access in Europe and many other countries, which remains its main revenue base.
The company is highly exposed to regulatory outcomes, especially for DrugSorb-ATR in the U.S...
Market acceptance risk
Hospitals and clinicians may not adopt the devices without sufficient evidence, reimbursement, and guideline support.
- Scope
- CytoSorb and new product launches
- Materiality
- high
Financing and going-concern risk
Cash resources and operating losses create dependence on external funding and cost reductions.
- Scope
- Corporate liquidity
- Materiality
- high
Competitive and reimbursement pressure
Competing technologies or unfavorable payer policies could reduce adoption and pricing power.
- Scope
- Global commercial markets
- Materiality
- medium
Nasdaq listing compliance
Failure to meet listing standards could hurt stock liquidity and investor access to capital.
- Scope
- Public equity market access
- Materiality
- medium
Revenue recognition
Affects quarterly comparability and growth rates
Going-concern assessment
Signals financing dependence and potential dilution
Restructuring charges
Impacts operating expenses and short-term earnings
Stock-based compensation
Non-cash expense affects profitability trends
Royalty expense
Affects gross margin and operating leverage
: 28.4.2026